Mieszczak C, Winther K
Department of Clinical Chemistry, Hvidovre Hospital, University of Copenhagen, Denmark.
Eur J Clin Pharmacol. 1993;44(2):205-6. doi: 10.1007/BF00315483.
We gave ketoprofen (100 mg bid) for 7 days, on a placebo-controlled, double-blind basis, to 15 healthy male volunteers already stabilized on warfarin in dosages which lowered the prothrombin time by about 60%. Ketoprofen did not affect the prothrombin time, there was no change in coagulation cascade parameters, and there was no clinical evidence of bleeding. We conclude that ketoprofen in this dosage has no significance effect on the anticoagulant effect of warfarin.
我们在安慰剂对照、双盲的基础上，给予15名已稳定服用华法林且剂量能使凝血酶原时间降低约60%的健康男性志愿者酮洛芬（100毫克，每日两次），持续7天。酮洛芬未影响凝血酶原时间，凝血级联参数无变化，也无出血的临床证据。我们得出结论，该剂量的酮洛芬对华法林的抗凝作用无显著影响。
